IQVIA
Market Access/ Views & Analysis/ Views and analysis
Nine for 2023, part three: thriving or surviving?
mike.hammerton@pharmaphorum.com
2023 predictions, competition, financing, HCPs, healthcare, IQVIA, pharma
0 Comment
Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms
mike.hammerton@pharmaphorum.com
2023 predictions, ageing, Alzheimer's, diagnostics, IQVIA, pharmacotherapies
0 Comment
Market Access/ Views & Analysis/ Views and analysis
It’s time get real with healthcare’s commitment to net zero
mike.hammerton@pharmaphorum.com
COP27, emissions, healthcare, IQVIA, net zero, pharma, Sustainability, United Nations
0 Comment
Market Access/ Slider in home page/ Views & Analysis/ Webinars/ Webinars in home page/ Webinars On demand
Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals
mike.hammerton@pharmaphorum.com
Innovative Medicines Fund, IQVIA, NHSE, NICE
0 Comment
Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Key operational considerations to optimise decentralised clinical trials
mike.hammerton@pharmaphorum.com
decentralised clinical trials, IQVIA, patient centricity, patient engagement, patient-centric trials, planning and design, research
0 Comment
R&D/ Views & Analysis/ Views and analysis
How to Successfully Employ External Comparator Arm Studies Using Real World Data
mike.hammerton@pharmaphorum.com
analysis, drug approval studies, endpoints, estimands, external comparator arm studies, IQVIA, precision medicine, randomised clinical trials, real world data, single arm trials
0 Comment
Insights/ Market Access/ Views & Analysis/ Views and analysis
Is the launch environment really more competitive now?
mike.hammerton@pharmaphorum.com
competitive intensity, IQVIA, launch environment, market data, pharma, primary care
0 Comment